The CCR/KI has a longstanding track record of using mice to study cancer. Over the last decade the Center has successfully generated numerous mouse models that develop tumors that closely resemble the human disease with regard to both the spectrum of contribufing mutations and their phenotypic characterisfics including progression to the metastafic state. There is now a strong drive by both Kl Scientists and Engineers to use these models to test potential therapeutic strategies and also explore mechanisms of drug resistance. Moreover, these models are a key resource for Kl Engineers, offering in vivo systems to test tumor detecfion and monitoring devices, drug delivery systems, and chemotherapeutic response. In the current funding period, the Kl has established a new facility, called the Applied Therapeutics &Whole Animal Imaging (ATWAI) Core Facility that exists as a centralized resource to support and encourage these translational efforts. The ATWAI Core developed in two phases. Inifially, the Core established the infrastructure necessary to support longitudinal studies of the response and resistance to therapeutic agents, particularly whole animal imaging modalities. This instrumentation has allowed Center members to assess tumor dynamics in vivo including tracking the development and metastasis of tumors and following their response to treatment. Next, in 2008, an expert in mouse models was recruited as Acting Manager of the ATWAI Core with the goal of minimizing the myriad hurdles that exist in setting up and conducting preclinical trials. The ATWAI manager provides Center members with a extensive and customized consultative services, investigator training, and handson execufion of experiments to enable on-site, high-quality in vivo trials for biosensors, diagnostics, vaccines, chemotherapies, gene therapy, or drug delivery and targefing modalifies. Thus, the ATWAI Core helps Center members to bring mouse models to bear on potenfial therapies, and spurs collaborafions between Kl engineers and scienfists to allow testing of drug delivery and tumor monitoring systems in appropriate in vivo models. An expansion of the ATWAI Core is planned for the new Koch Institute building, including addifional staff and instrumentation. Support from the CCSG is critical to ensure the success of this ATWAI Core, a goal that fits perfecfiy with the NCI's desire to advance translational research.
| Rothenberg, Daniel A; Taliaferro, J Matthew; Huber, Sabrina M et al. (2018) A Proteomics Approach to Profiling the Temporal Translational Response to Stress and Growth. iScience 9:367-381 |
| Kimmerling, Robert J; Prakadan, Sanjay M; Gupta, Alejandro J et al. (2018) Linking single-cell measurements of mass, growth rate, and gene expression. Genome Biol 19:207 |
| Tang, Li; Zheng, Yiran; Melo, Mariane Bandeira et al. (2018) Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol 36:707-716 |
| Holec, Patrick V; Berleant, Joseph; Bathe, Mark et al. (2018) A Bayesian framework for high-throughput T cell receptor pairing. Bioinformatics : |
| Wong, Madeline Y; Doan, Ngoc Duc; DiChiara, Andrew S et al. (2018) A High-Throughput Assay for Collagen Secretion Suggests an Unanticipated Role for Hsp90 in Collagen Production. Biochemistry 57:2814-2827 |
| Danai, Laura V; Babic, Ana; Rosenthal, Michael H et al. (2018) Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558:600-604 |
| Dubbury, Sara J; Boutz, Paul L; Sharp, Phillip A (2018) CDK12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature 564:141-145 |
| Tokatlian, Talar; Kulp, Daniel W; Mutafyan, Andrew A et al. (2018) Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. Sci Rep 8:16527 |
| Crowell, Laura E; Lu, Amos E; Love, Kerry R et al. (2018) On-demand manufacturing of clinical-quality biopharmaceuticals. Nat Biotechnol : |
| Lo, Justin H; Hao, Liangliang; Muzumdar, Mandar D et al. (2018) iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 17:2377-2388 |
Showing the most recent 10 out of 904 publications
